Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention
Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention
米非司酮堕胎药的供应陷入困境：司法部可能会要求最高法院进行干预
- U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of the abortion pill mifepristone.
- Garland said the administration "will be seeking emergency relief from the Supreme Court to defend the FDA's scientific judgment and protect Americans' access to safe and effective reproductive care."
- The New Orleans-based 5th U.S. Circuit Court of Appeals put on hold part of last Friday's order by U.S. District Judge Matthew Kacsmaryk in Amarillo, Texas, while he hears a lawsuit by anti-abortion groups seeking to ban it.
- The Planned Parenthood Federation of America condemned the 5th Circuit's decision as a rejection of science and law.
- "The federal judiciary has — for the second time this week — rejected science and the law, and this time, the court decided they had the authority to re-write mifepristone's label," CNBC reported citing Alexis McGill Johnson, president of Planned Parenthood.
- "If allowed to stand, the consequences of this decision will be catastrophic not just for medication abortion access but the entire drug approval system," he added.
- A U.S. federal appeals court has temporarily blocked a decision by a Texas judge.
- The abortion pill mifepristone will remain available in the U.S. for now but with some restrictions, including requiring in-person doctor visits to obtain the drug and limiting its use to the first seven weeks of pregnancy from the current ten, a federal appeals court ruled.
- 美国司法部长梅里克·加兰说，司法部将向美国最高法院提起上诉，要求阻止Kacsmaryk暂停美国食品药品管理局批准堕胎药米非司酮的全部命令。
- 加兰说，政府 “将向最高法院寻求紧急救济，以捍卫美国食品药品管理局的科学判断，保护美国人获得安全有效的生殖保健的机会。”
- 总部位于新奥尔良的美国第五巡回上诉法院暂停了美国地方法院法官马修·卡斯马里克上周五在德克萨斯州阿马里洛下达的部分命令，当时他正在审理反堕胎组织提起的旨在禁止该命令的诉讼。
- 美国计划生育联合会谴责第五巡回法院的决定，认为这是对科学和法律的拒绝。
- CNBC援引计划生育组织主席亚历克西斯·麦吉尔·约翰逊的话报道：“联邦司法机构本周第二次拒绝了科学和法律，这次，法院裁定他们有权改写米非司通的标签。”
- 他补充说：“如果允许的话，这一决定的后果将是灾难性的，不仅会影响药物流产的获取，而且会影响整个药物批准系统。”
- 美国联邦上诉法院暂时阻止了得克萨斯州法官的裁决。
- 联邦上诉法院裁定，堕胎药米非司酮目前仍将在美国上市，但有一些限制，包括要求当面看医生才能获得该药物，并将其使用从目前的十周限制在妊娠的前七周。